Home Portfolio Partnering
Partnering with CASI Pharmaceuticals
CASI is committed to building a product portfolio of innovative therapeutics, initially focusing on hematology-oncology diseases. Working collaboratively with our partners, CASI is a trusted U.S. partner for companies who want to bring their innovative therapies into the China market. Leveraging our U.S. and China hematology-oncology expertise and resources, our goal is to work closely with partners to develop and commercialize products rapidly and effectively. Our extensive relationships with key hematologists and oncologists and the premier cancer hospitals in China ensures high-quality clinical data is generated under ICH GCP standards to support global registrations.

CASI has built a fully integrated, world class biopharmaceutical company dedicated to the successful development and commercialization of innovative medicines. We are a U.S. Nasdaq-listed company with China and U.S. operations and dedicated management teams with deep knowledge of global drug development, tech transfer & commercialization in both China & the U.S. With over 200 employees in China and the U.S., CASI personnel are trained in global operations and have extensive expertise in U.S./China clinical, regulatory and commercial requirements and standards.

Regulatory Affairs Group - strong working relationships with the NMPA (China FDA) and US FDA – track record of successful filings/approvals

Clinical/Medical Team - extensive industry experience in oncology/hematology - strong network with the top KOLs/PIs in China

Clinical Operations and Pharmacovigilance Team - specialized in the management of clinical projects and study site data and reporting

Marketing and Sales Organization – team of experienced oncology/hematology marketing and sales professionals – successful launch of EVOMELA®

CASI welcomes partnership opportunities with companies and academic/research institutions that are developing innovative therapeutics for hematologic malignancies and solid tumors.
Selected Partners
Acrotech Biopharma LLC

Acquired exclusive China rights for three U.S. FDA-approved marketed products:
EVOMELA® (melphalan for injection), ZEVALIN® (ibritumomab tiuxetan), MARQIBO® (vincristine sulfate LIPOSOME injection)

BioInvent International AB

License agreement for exclusive China rights for first-in-class anti-FcyRIIB monoclonal antibody (BI1206)

Juventas Cell Therapy, LtD.

License agreement for exclusive worldwide license and commercialization rights to an autologous anti-CD19 T-cell therapy product (CNCT19)

Black Belt Therapeutics

License agreement for exclusive worldwide rights to a novel anti-CD38 monoclonal antibody (CID-103)

Esteve Pharmaceuticals, S.A.

License agreement for exclusive China rights for a novel formulation of Thiotepa

Cleave Therapeutics

License agreement for exclusive Greater China Region First-in-Class VCP/P97 Inhibitor CB-5339

China Resources Guokang Pharmaceutics Co., Ltd

Distributor for importing and distributing Evomela in the Territory

For more information about partnering with CASI Pharmaceuticals and our Business Development group,
please contact us via email to: partnering@casipharmaceuticals.com.